Clinical progress of HIV-1 integrase inhibitors

Expert Opinion on Emerging Drugs

Volumn 13, Issue 2, 2008, Pages 213-225

  Al Mawsawi, Laith Q ^a   Al Safi, Rasha I ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AIDS; Antiretroviral; HIV; Integrase; Therapeutics

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ABACAVIR; ANTIRETROVIRUS AGENT; BMS 707035; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; GS 9160; GS 9224; GSK 364735; INTEGRASE; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MK 2048; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG INFORMATION; DRUG RESEARCH; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; KIDNEY DISEASE; LIVER TOXICITY; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; VOMITING; DRUG DESIGN; DRUG EFFECT; DRUG INTERACTION;

ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INTERACTIONS; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS;

EID: 46949098038     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.2.213     Document Type: Review

References (50)

1. Saksena NK, Potter SJ. Reservoirs of HIV-: in vivo: implications for antiretroviral therapy. AIDS Rev 2003;5:3-18
2. Potter SJ, Dwyer DE, Saksena NK. Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART. Virology 2003;305:339-52
3. Potter SJ, Lemey P, Dyer WB, et al. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. Virology 2006;348:35-46
4. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006;41:439-46
5. Shet A, Markowitz M. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Curr Opin Investig Drugs 2006;7:709-20
6. Wainberg MA, Sawyer JP, Montaner JS, et al. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antivir Ther 2005;10:13-28
7. Yusa K, Harada S. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Des 2004;10:4055-64
8. Esser S, Helbig D, Hillen U, et al. Side effects of HIV therapy. J Dtsch Dermatol Ges 2007;5:745-54
9. Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health Syst Pharm 2004;61:2507-22
10. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14:499-507
11. Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R&D 2007;8:155-68
12. Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: 2005 - 2006 update. Med Res Rev 2007;28:118-54
13. Neamati N. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin Ther Patents 2002;12:709-24
14. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4:236-48
15. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs 2006; 15:1507-22
16. Nair V, Chi G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev Med Virol 2007;17:277-95
17. Billich A. S-1360 Shionogi-GlaxoSmith Kline. Curr Opin Investig Drugs 2003;4:206-9
18. Yoshinaga T, Sato A, Fujishita T, Fujiwara T. S-1360: in vitro activity of a new HIV-1 integrase inhibitor in clinical development. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24 - 28; Seattle, WA [abstract 8]
19. Rosemond MJ, St John-Williams L, Yamaguchi T, et al. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 2004;147:129-39
20. Egbertson MS. HIV integrase inhibitors: from diketoacids to heterocyclic templates: a history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM). Curr Top Med Chem 2007;7:1251-72
21. Brown PO. Integration. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1997. p. 161-203
22. Guiot E, Carayon K, Delelis O, et al. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem 2006;281:22707-19
23. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-9
24. LaFemina RL, Schneider CL, Robbins HL, et al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992;66:7414-9
25. MK-0518 meeting transcript. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research; Antiviral Drugs Advisory Committee; 2007 September 5. Available from: www.fda.gov/ohrms/ dockets/ac/cder07.htm#AntiviralDrugs [Last accessed 1 November 2007]
26. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 105aLB]
27. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 105bLB]
28. Kassahun K, Mcintosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35:1657-63
29. Vacca J, Wai J, Fisher T, et al. Discovery of MK-2048: subde changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors. 4th International AIDS Society (IAS) Conference; 2007 Jul 22 - 25; Sydney, Australia
30. Wai J, Fisher T, Embrey M, et al. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 87]
31. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006;49:1506-8
32. Dejesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5
33. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 143LB]
34. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007;45:274-9
35. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr 2007;46:160-6
36. Ramanathan S, West S, Kakuda TN, et al. Lack of clinically relevant drug interactions between ritonavir-boosted elvitegravir and TMC125. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17 - 20; Chicago, IL [abstract H-1049]
37. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48
38. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38
39. Ramanathan S, West S, Abel S, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir plus maraviroc. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17 - 20; Chicago, IL [abstract H-1050]
40. Lalezari J, Goodrich J, Dejesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 104bLB]
41. Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 104aLB]
42. Shimura K, Kodama E, Sakagami Y, et al. Broad anti-retroviral activity and resistance profile of a novel human immunodeficiency virus integrase inhibitor, elvitegravir (JTK-303/GS-9137). J Virol 2007;82:764-74
43. Jones G, Ledford R, Yu F, et al. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 627]
44. Daelemans D, Lu R, De Clercq E, Engelman A. Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. J Virol 2007;81:4381-5
45. Garvey E, Johns B, Foster S, et al. GSK364735 is a Potent Inhibitor of HIV Integrase and Viral Replication. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17-20; Chicago, IL [abstract H-1048]
46. Golden PL, Piscitelli S, Min S, et al. In vitro antiviral potency and preclinical pharmacokinetics of GSK364735 predict clinical efficacy in a phase 2a study. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17-20; Chicago, IL [abstract H-1047]
47. Reddy S, Min S, Borland J, et al. A double-blind, parallel, randomized, placebo-controlled, single and repeat dose-escalation study to investigate the safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor GSK364735 in healthy subjects (GRZ105655). 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 562]
48. Low A, Mohri H, Markowitz M. Frequency of naturally occurring polymorphisms associated with resistance to integrase inhibitors in a recently infected cohort. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25 - 28; Los Angeles, CA [abstract 625]
49. A multiple ascending dose study of BMS-707035 in HIV-1 infected subjects: trial identifier NCT00397566. Available from: http://clinicaltrials.gov/ct2/ show/ NCT00397566 [Last accessed 6 December 2007]
50. Little S, Drusano G, Schooley R, et al. Antiviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1 infected patients. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22 - 25; Boston, MA [abstract 161]